Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | RAMP1 | O60894 | 1/20 | 0.37 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.37 |
| ▸ | BDKRB1 | P46663 | 2/20 | 0.35 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.35 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | MLNR | O43193 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4798589 | 0.84 | TEAD1 (0.36) | RAMP1CALCRLBDKRB1ADRB2EPHX2 | |
| SCHEMBL4849670 | 0.78 | RAMP1 (0.45) | CNR1RAMP1CALCRLEPHX2KMT2A | |
| SCHEMBL4804847 | 0.77 | OPRD1 (0.43) | CNR1RAMP1CALCRLADRB2EPHX2 | |
| SCHEMBL7290995 | 0.66 | HTR3A (0.55) | MEN1KMT2A | |
| SCHEMBL5248989 | 0.65 | RAMP1 (0.42) | RAMP1CALCRLADRB2EPHX2 | |
| SCHEMBL13361289 | 0.64 | RAMP1 (0.48) | RAMP1CALCRLADRB2EPHX2 | |
| SCHEMBL3309774 | 0.63 | NAAA (0.40) | ADRB2CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL3309780 | 0.63 | NAAA (0.40) | ADRB2CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL3314758 | 0.62 | RAMP1 (0.59) | RAMP1CALCRLADRB2EPHX2 | |
| SCHEMBL3314750 | 0.62 | RAMP1 (0.59) | RAMP1CALCRLADRB2EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7439237-B2 | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-10-21 | — | — | US | disclosed |
| US-20070238715-A1 | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238715-A1 | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | CALCRL, CALCR, CALCA | CNR1 91/4885RAMP1 46/4885CALCRL 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.